Precision BioSciences, Inc. PBS.F Stock
Precision BioSciences, Inc. Price Chart
Precision BioSciences, Inc. PBS.F Financial and Trading Overview
Precision BioSciences, Inc. stock price | 0.31 EUR |
Previous Close | 0.6 EUR |
Open | 0.61 EUR |
Bid | 0.61 EUR x 0 |
Ask | 0.63 EUR x 0 |
Day's Range | 0.61 - 0.61 EUR |
52 Week Range | 0.61 - 2 EUR |
Volume | 550 EUR |
Avg. Volume | 13 EUR |
Market Cap | 68.84M EUR |
Beta (5Y Monthly) | 1.381146 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 19.13 EUR |
PBS.F Valuation Measures
Enterprise Value | -58138296 EUR |
Trailing P/E | N/A |
Forward P/E | -0.24693878 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 2.2527 |
Price/Book (mrq) | 1.7042254 |
Enterprise Value/Revenue | -1.902 |
Enterprise Value/EBITDA | 0.648 |
Trading Information
Precision BioSciences, Inc. Stock Price History
Beta (5Y Monthly) | 1.381146 |
52-Week Change | -44.53% |
S&P500 52-Week Change | 20.43% |
52 Week High | 2 EUR |
52 Week Low | 0.61 EUR |
50-Day Moving Average | 0.73 EUR |
200-Day Moving Average | 1.11 EUR |
PBS.F Share Statistics
Avg. Volume (3 month) | 13 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 113.79M |
Float | 80.74M |
Short Ratio | N/A |
% Held by Insiders | 15.08% |
% Held by Institutions | 50.62% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -319.017% |
Gross Margin | 100.00% |
EBITDA Margin | -293.55% |
Management Effectiveness
Return on Assets (ttm) | -31.58% |
Return on Equity (ttm) | -197.62% |
Income Statement
Revenue (ttm) | 30.56M EUR |
Revenue Per Share (ttm) | 0.3 EUR |
Quarterly Revenue Growth (yoy) | 164.69% |
Gross Profit (ttm) | 25.1M EUR |
EBITDA | -89712000 EUR |
Net Income Avi to Common (ttm) | -108529000 EUR |
Diluted EPS (ttm) | -0.9 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 158.13M EUR |
Total Cash Per Share (mrq) | 1.39 EUR |
Total Debt (mrq) | 26.6M EUR |
Total Debt/Equity (mrq) | 66.2 EUR |
Current Ratio (mrq) | 3.607 |
Book Value Per Share (mrq) | 0.355 |
Cash Flow Statement
Operating Cash Flow (ttm) | -48345000 EUR |
Levered Free Cash Flow (ttm) | -12746750 EUR |
Profile of Precision BioSciences, Inc.
Country | Germany |
State | NC |
City | Durham |
Address | 302 East Pettigrew Street |
ZIP | 27701 |
Phone | 919 314 5512 |
Website | https://www.precisionbiosciences.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 197 |
Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Q&A For Precision BioSciences, Inc. Stock
What is a current PBS.F stock price?
Precision BioSciences, Inc. PBS.F stock price today per share is 0.31 EUR.
How to purchase Precision BioSciences, Inc. stock?
You can buy PBS.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Precision BioSciences, Inc.?
The stock symbol or ticker of Precision BioSciences, Inc. is PBS.F.
Which industry does the Precision BioSciences, Inc. company belong to?
The Precision BioSciences, Inc. industry is Biotechnology.
How many shares does Precision BioSciences, Inc. have in circulation?
The max supply of Precision BioSciences, Inc. shares is 4.84M.
What is Precision BioSciences, Inc. Price to Earnings Ratio (PE Ratio)?
Precision BioSciences, Inc. PE Ratio is 0.00000000 now.
What was Precision BioSciences, Inc. earnings per share over the trailing 12 months (TTM)?
Precision BioSciences, Inc. EPS is 0 EUR over the trailing 12 months.
Which sector does the Precision BioSciences, Inc. company belong to?
The Precision BioSciences, Inc. sector is Healthcare.